Czechoslovak Group (CSG) & Excalibur Army: Valuation, Ammunition and the Czech Shell Initiative
Czechoslovak Group (CSG), the family conglomerate controlled by Michal Strnad, has become one of the most consequential defense companies of the Ukraine war — not for a single flagship weapon, but for ammunition. CSG and its subsidiary Excalibur Army sit at the heart of the “Czech ammunition initiative,” which scours the world for 155mm artillery shells and channels them to Ukraine. The group was privately held for most of its history; that changed in January 2026, when it staged what was reported as the largest defense IPO ever, valued near €25 billion. This page explains its scale, its finances and its central role in keeping Ukrainian guns supplied.
CSG and Excalibur Army
The group's origins are modest. In 1995 Jaroslav Strnad founded Excalibur Army with fewer than twenty employees and a tiny amount of capital, overhauling Soviet-era military equipment. Over the following decades the business expanded by acquisition into a sprawling conglomerate spanning ammunition, armored vehicles, aerospace components and rail. His son Michal Strnad took control in 2018 and consolidated the defense assets under the Czechoslovak Group banner.
Today CSG produces and refurbishes large-caliber ammunition, artillery, armored vehicles and related systems across plants in Czechia and beyond, having also expanded into the United States. Excalibur Army remains the historical and industrial core of the group, one of the manufacturers underpinning its large-caliber shell output. What makes CSG unusual is the combination of in-house manufacturing with an extensive global trading and sourcing network — a network that proved decisive once Europe's shell shortage became acute.
The Czech Ammunition Initiative
In February 2024, at the Munich Security Conference, Czech President Petr Pavel announced an initiative to buy artillery shells for Ukraine from producers worldwide, using Czech industry's contacts to reach sellers outside Europe that other governments could not easily access. The initial goal was on the order of 800,000 large-caliber rounds, funded by a coalition of donor nations.
CSG and its trading arms were among the key Czech players able to source and broker that ammunition. Delivery figures depend on how they are counted, but by the end of 2024 the initiative had supplied hundreds of thousands of 155mm rounds, reported as meeting around 80% of its first-year target. Roughly 1.5 million large-caliber shells had reached Ukraine by early 2025, and cumulative deliveries of large-caliber ammunition were later reported in the millions. The scheme has drawn some criticism over pricing, quality control and transparency, but it kept a steady flow of shells moving when Western stockpiles were exhausted.
⚠ Shell-delivery counts vary by source and caliber definition (source); treat them as approximate.
Revenue and Growth
CSG's financial trajectory has been extraordinary. Reported consolidated revenue rose from only a few hundred million euros at the start of the decade to about €4 billion in 2024, an increase of roughly 131% in a single year, with operating EBITDA above €1 billion. Defense accounted for the large majority of sales.
Crucially, Ukraine became CSG's second-largest market, with sales there reported at about €1.7 billion in 2024 — a direct measure of how central the war has been to the group's growth. That kind of expansion, combined with public bond issuances that exposed CSG's finances to investors, gradually turned a quiet family firm into one of Europe's most closely watched defense businesses.
⚠ Revenue, EBITDA and Ukraine-sales figures from CSG's 2024 results and Reuters/Bloomberg reporting (source); approximate.
Valuation: From Private to Listed
For most of its history CSG was privately held and not exchange-listed, so it had no daily market price. Analysts therefore inferred its worth from private-company signals: rapid revenue and EBITDA growth, bond issuances, pre-IPO valuation talk and the Strnad family's billionaire estimates. Bloomberg's Billionaires Index has estimated Michal Strnad's fortune in the tens of billions of dollars, ranking him the richest person in the Czech Republic.
That changed on 23 January 2026, when CSG listed on Euronext Amsterdam in what was reported as the largest defense IPO in history, valued at about €25 billion and raising roughly €3.8 billion. The shares jumped about 30% on debut, briefly lifting the market value above €30 billion and making CSG one of the most valuable listed companies in Central Europe. Strnad sold only around a 15% stake and retained majority control, so CSG is now a listed but founder-controlled group rather than a fully float-traded one.
| Valuation signal | Reported value |
|---|---|
| Consolidated revenue 2024 | ~€4.0B (+131% YoY) |
| Operating EBITDA 2024 | ~€1.1B |
| Ukraine sales 2024 | ~€1.7B (2nd-largest market) |
| Strnad net worth (Bloomberg est.) | tens of $bn |
| IPO valuation (23 Jan 2026) | ~€25B (largest defense IPO) |
| First-day market value | ~€30B+ after ~30% pop |
⚠ Pre-IPO values are external estimates; the IPO valuation is from Euronext, CNBC and Bloomberg reporting (source). Approximate. Not investment advice.
Why It Matters for Ukraine
Artillery has been the dominant killer of the war, and Ukrainian shell consumption has at times run far ahead of what allied stockpiles and Western production lines could replace. In that environment, the ability to find, buy and ship 155mm rounds from wherever they exist became as strategically valuable as the ability to make them. CSG combined both, which is why it ended up so central to the Czech initiative and to the broader Western effort to keep Ukrainian guns firing.
The group's rise also illustrates a wider shift: Central European defense industry, long overshadowed by the big Western primes, has moved to the front of the rearmament story. CSG's transformation from a family overhaul business into a multi-billion-euro listed conglomerate is one of the clearest commercial markers of how the war reshaped Europe's defense map.
Key Data
| Metric | Value |
|---|---|
| Listing status | Listed on Euronext Amsterdam since 23 Jan 2026 (private before; founder-controlled) |
| Country | Czech Republic |
| Owner / control | Michal Strnad (majority control retained after IPO) |
| Core subsidiary | Excalibur Army (founded 1995) |
| Revenue 2024 (approx.) | ~€4.0B (+131% YoY) |
| IPO valuation (Jan 2026) | ~€25B |
| Ukraine relevance | Central to the Czech ammunition initiative sourcing 155mm shells worldwide; Ukraine is its 2nd-largest market. |
Frequently Asked Questions
What is Czechoslovak Group (CSG)?
CSG (Czechoslovak Group) is a Czech industrial and defense conglomerate controlled by Michal Strnad. It traces its roots to Excalibur Army, founded by his father Jaroslav Strnad in 1995. CSG makes and refurbishes armored vehicles, weapons and large-caliber ammunition and has become one of Europe's fastest-growing defense groups.
Is CSG publicly listed or private?
CSG was privately held for most of its history. That changed on 23 January 2026, when it listed on Euronext Amsterdam in what was reported as the largest defense IPO ever, valued at about €25 billion. Founder Michal Strnad sold roughly a 15% stake while retaining majority control, so the company is now listed but founder-controlled.
What is the Czech ammunition initiative?
The Czech ammunition initiative is a procurement scheme announced by Czech President Petr Pavel at the Munich Security Conference in February 2024. Using Czech industry's global contacts, it sources 155mm and other large-caliber artillery shells worldwide and channels them to Ukraine, funded by a coalition of donor nations.
How many shells has the Czech initiative delivered to Ukraine?
Reported figures vary by definition. By the end of 2024 the initiative had delivered hundreds of thousands of 155mm rounds, meeting around 80% of its first-year target, and roughly 1.5 million large-caliber shells had reached Ukraine by early 2025. Cumulative deliveries of large-caliber ammunition were later reported in the millions of rounds.
What is Excalibur Army's role?
Excalibur Army is the CSG subsidiary at the historical core of the group. It overhauls and produces artillery, armored vehicles and ammunition, and is one of the manufacturers underpinning CSG's large-caliber output. It is the company from which the wider group grew after 1995.
How much revenue does CSG make?
CSG reported consolidated revenue of about €4 billion in 2024, up roughly 131% year on year, with operating EBITDA above €1 billion. Ukraine became its second-largest market, with sales there reported at about €1.7 billion. Revenue had climbed from only a few hundred million euros a few years earlier.
How rich is Michal Strnad?
Bloomberg's Billionaires Index has estimated Michal Strnad's fortune in the tens of billions of dollars, making him the wealthiest person in the Czech Republic and, by some rankings, in Central Europe. These are external estimates that move with CSG's market value and should be treated as approximate.
How was CSG valued before its IPO?
Before the January 2026 listing CSG was private, so it had no daily market price. Analysts inferred its value from private-company signals: explosive revenue and EBITDA growth, bond issuances that exposed its finances to investors, the Strnad family's billionaire estimates and pre-IPO valuation talk. The IPO then crystallized a value near €25 billion.
Why is CSG so important to Ukraine?
Artillery has been central to the war and Ukraine's shell consumption has been enormous. CSG's manufacturing capacity and its trading network, which sources shells from producers around the world, made it one of the linchpins of the Czech initiative and of Western efforts to keep Ukrainian guns supplied.
Where can I verify CSG's figures?
CSG's revenue and EBITDA come from its own annual results and reporting by Reuters and Bloomberg; the IPO valuation from Euronext, CNBC and Bloomberg; Strnad's wealth from the Bloomberg Billionaires Index; and shell-delivery counts from the Czech government and outlets such as Militarnyi and Euromaidan Press. These are approximate and this page is analysis, not investment advice.